INT5458

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.54
First Reported 1981
Last Reported 2008
Negated 0
Speculated 1
Reported most in Abstract
Documents 31
Total Number 32
Disease Relevance 10.58
Pain Relevance 8.89

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (Tbxa2r) signal transducer activity (Tbxa2r)
Anatomy Link Frequency
blood 6
plasma 4
platelet 4
superior 1
endothelium 1
Tbxa2r (Rattus norvegicus)
Pain Link Frequency Relevance Heat
antagonist 17 100.00 Very High Very High Very High
cINOD 25 99.98 Very High Very High Very High
adenocard 1 99.80 Very High Very High Very High
aspirin 37 99.62 Very High Very High Very High
Angina 21 99.36 Very High Very High Very High
Pain 9 99.24 Very High Very High Very High
epidural 8 99.08 Very High Very High Very High
Sciatica 2 98.92 Very High Very High Very High
anesthesia 4 98.70 Very High Very High Very High
Inflammation 26 98.60 Very High Very High Very High
Disease Link Frequency Relevance Heat
Thrombosis Related Under Development 8 99.56 Very High Very High Very High
Cv General 3 Under Development 20 99.36 Very High Very High Very High
Coagulation Disorder 2 99.36 Very High Very High Very High
Nerve Root Compression 2 98.92 Very High Very High Very High
INFLAMMATION 33 98.60 Very High Very High Very High
Diabetes Mellitus 16 98.56 Very High Very High Very High
Adhesions 9 97.36 Very High Very High Very High
Hyperalgesia 6 96.76 Very High Very High Very High
Coronary Artery Disease 11 96.40 Very High Very High Very High
Body Weight 3 94.84 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Two weeks and 28 weeks after the induction of diabetes, renal blood flow (RBF) under anesthesia was measured with an electromagnetic flowmeter before and after TXA2 inhibition.
Negative_regulation (inhibition) of TXA2 in blood associated with anesthesia and diabetes mellitus
1) Confidence 0.54 Published 1994 Journal Kidney Int. Section Abstract Doc Link 8196281 Disease Relevance 0.43 Pain Relevance 0.18
The concentration-dependent constriction induced by clonidine was analyzed in the absence and presence of the nitric oxide synthase (NOS) inhibitor, Nomega-nitro-L-arginine (L-NAME), cyclooxygenase (COX-1 and COX-2) inhibitors, indomethacin, the specific COX-2 inhibitor NS-398, the thromboxane-prostanoid receptor antagonist SQ29,548 and the thromboxane A2 (TXA2) synthase inhibitor, furegrelate.
Negative_regulation (inhibitor) of thromboxane A2 associated with antagonist, cox-2 inhibitor and clonidine
2) Confidence 0.46 Published 2006 Journal J. Vasc. Res. Section Abstract Doc Link 16293968 Disease Relevance 0 Pain Relevance 0.42
Epidural injection of LTB4 receptor antagonist and/or TXA2 synthetase inhibitor may attenuate the painful radiculopathy due to lumbar disc herniation.
Negative_regulation (inhibitor) of TXA2 associated with pain, antagonist, sciatica and epidural
3) Confidence 0.43 Published 2001 Journal J. Orthop. Res. Section Abstract Doc Link 11398862 Disease Relevance 0.55 Pain Relevance 0.92
TXA2 synthetase inhibitor and LTB4 receptor antagonist, which were injected into the epidural space, decreased mechanical hyperalgesia at both three and seven days after epidural injection.
Negative_regulation (inhibitor) of TXA2 associated with hyperalgesia, antagonist and epidural
4) Confidence 0.43 Published 2001 Journal J. Orthop. Res. Section Abstract Doc Link 11398862 Disease Relevance 0.59 Pain Relevance 0.84
Acute and chronic effects of thromboxane A2 inhibition on the renal hemodynamics in streptozotocin-induced diabetic rats.
Negative_regulation (inhibition) of thromboxane A2 associated with diabetes mellitus
5) Confidence 0.35 Published 1994 Journal Kidney Int. Section Title Doc Link 8196281 Disease Relevance 0.42 Pain Relevance 0.16
The concentration-dependent constriction induced by clonidine was analyzed in the absence and presence of the nitric oxide synthase (NOS) inhibitor, Nomega-nitro-L-arginine (L-NAME), cyclooxygenase (COX-1 and COX-2) inhibitors, indomethacin, the specific COX-2 inhibitor NS-398, the thromboxane-prostanoid receptor antagonist SQ29,548 and the thromboxane A2 (TXA2) synthase inhibitor, furegrelate.
Negative_regulation (inhibitor) of TXA2 associated with antagonist, cox-2 inhibitor and clonidine
6) Confidence 0.30 Published 2006 Journal J. Vasc. Res. Section Abstract Doc Link 16293968 Disease Relevance 0 Pain Relevance 0.42
A similar concentration-dependent inhibition of the antigen response was observed with two thromboxane A2 receptor blockers, SK&F 88046 and KW-3635.
Negative_regulation (blockers) of thromboxane A2
7) Confidence 0.29 Published 1997 Journal Zentralbl Veterinarmed A Section Abstract Doc Link 9342927 Disease Relevance 0 Pain Relevance 0.16
Effect of synthesis inhibitors of thromboxane A2 and prostaglandin E2 on the regulation of sodium and water.
Negative_regulation (inhibitors) of thromboxane A2
8) Confidence 0.28 Published 1989 Journal J. Pharmacol. Exp. Ther. Section Title Doc Link 2810118 Disease Relevance 0 Pain Relevance 0.17
Bepridil also significantly decreased the plasma levels of thromboxane B2 and leukotriene C4 at rest.
Negative_regulation (decreased) of thromboxane B2 in plasma
9) Confidence 0.25 Published 1994 Journal Am. J. Cardiol. Section Abstract Doc Link 8198031 Disease Relevance 0.53 Pain Relevance 0.26
The results showed that Sustanon 250 administration increased plasma ANP levels, decreased TXA2 and increased PGI2 levels significantly, and thereby improved the TXA2/PGI2 imbalance in CHD patients (all P < 0.01).
Negative_regulation (decreased) of TXA2 in plasma associated with coronary artery disease
10) Confidence 0.20 Published 1993 Journal Chin. Med. Sci. J. Section Abstract Doc Link 8032065 Disease Relevance 0.92 Pain Relevance 0.10
In a second study, ridogrel, an inhibitor of thromboxane synthetase as well as a thromboxane A2 receptor blocker, also showed significant efficacy in reducing peritoneal adhesion severity.
Negative_regulation (inhibitor) of thromboxane A2 receptor associated with adhesions
11) Confidence 0.16 Published 1995 Journal J Invest Surg Section Abstract Doc Link 7547726 Disease Relevance 0.74 Pain Relevance 0.53
Normal rats given single oral doses of BF389 had significant suppression of arachidonate-stimulated whole blood prostaglandin E2 and thromboxane B2 production 2 hr postdosing (ED50 = 0.1 mg/kg).
Negative_regulation (suppression) of thromboxane B2 production 2 in blood
12) Confidence 0.09 Published 1992 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 1309875 Disease Relevance 0.99 Pain Relevance 0.48
Selective thromboxane A2 synthetase inhibition in vasospastic angina pectoris.
Negative_regulation (inhibition) of thromboxane A2 associated with angina
13) Confidence 0.09 Published 1986 Journal J. Am. Coll. Cardiol. Section Title Doc Link 3941213 Disease Relevance 0.28 Pain Relevance 0.28
Cardioprotection of nitro-naproxen, ISDN and L-arginine involve nitrites/nitrates and PGI2-increased in the circulation associated to a reduction of thromboxane B2 (TXB2) in the blood.
Negative_regulation (reduction) of thromboxane B2 in blood
14) Confidence 0.06 Published 2006 Journal Pharmacol. Res. Section Abstract Doc Link 16488624 Disease Relevance 0.55 Pain Relevance 0.10
Levels of thromboxane B2 (TXB2), the catabolite of TXA2, were reduced in treated animals at 6 and 12 hours but these changes were not significant.
Negative_regulation (reduced) of thromboxane B2
15) Confidence 0.03 Published 1984 Journal Cornell Vet Section Abstract Doc Link 6587959 Disease Relevance 0.26 Pain Relevance 0.25
The effects of ozagrel, a thromboxane A2 (TXA2) synthase inhibitor, and CV-3988, a platelet activating factor (PAF) antagonist, was investigated on the repeatedly antigenic challenge-induced airway hyperresponsiveness (AHR) in rats.
Negative_regulation (inhibitor) of TXA2 in platelet associated with antagonist
16) Confidence 0.03 Published 1994 Journal Res. Commun. Chem. Pathol. Pharmacol. Section Abstract Doc Link 7938906 Disease Relevance 0 Pain Relevance 0.09
Current antiplatelet agents are designed to inhibit various mediators of platelet activation, such as thromboxane A2 and adenosine diphosphate, and platelet-surface receptors (e.g., glycoprotein IIb/IIIa receptors).
Negative_regulation (inhibit) of thromboxane A2 in platelet associated with adenocard
17) Confidence 0.03 Published 2008 Journal J Interv Cardiol Section Abstract Doc Link 19090933 Disease Relevance 0.24 Pain Relevance 0.15
BACKGROUND: Combined thromboxane A2 receptor blockade and thromboxane synthetase inhibition facilitates local prostacyclin production at the site of platelet activation thereby providing a potent antithrombotic effect.
Negative_regulation (blockade) of thromboxane A2 receptor in platelet
18) Confidence 0.02 Published 1997 Journal Basic Res. Cardiol. Section Abstract Doc Link 9226103 Disease Relevance 0.07 Pain Relevance 0.18
Although carprofen produced moderate suppression of serum thromboxane B2 and exudate prostaglandin E2 synthesis, these effects were not related to carprofen concentrations in plasma or exudate.
Negative_regulation (suppression) of thromboxane B2 in plasma
19) Confidence 0.02 Published 1994 Journal Equine Vet. J. Section Abstract Doc Link 8542839 Disease Relevance 0.34 Pain Relevance 0.24
The cardio-protective properties arise form its judicious inhibition of platelet-derived thromboxane A2 over prostacyclin, while its anti-inflammatory effects of aspirin stem from its well-established inhibition of prostaglandin (PG) synthesis within inflamed tissues.
Negative_regulation (inhibition) of thromboxane A2 in stem associated with aspirin and inflammation
20) Confidence 0.02 Published 2006 Journal ScientificWorldJournal Section Abstract Doc Link 16951898 Disease Relevance 0.57 Pain Relevance 0.62

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox